Drug intelligence / Profile preview

KP501

Development stage: Preclinical
Lead developer: 科越医药

Overview

KP501 is a long-acting biologic developed by Kira Pharmaceuticals, utilizing its LOGIC drug discovery platform. It is designed to target and modulate the classical and lectin pathways of the complement system. This investigational agent is currently in preclinical development for the treatment of autoantibody-mediated disorders, hemolytic disorders, rheumatologic disorders, and certain neurological diseases.

Targets

MASP (MASP family)

Beyond the preview

Go deeper on KP501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP501.

Explore the full profile